Generic Medicine Info
Should be taken on an empty stomach. Take on an empty stomach. May be taken at bedtime to reduce occurrence of nausea.
Previous failure of tumour response to other nitrosoureas; severe bone marrow depression, coeliac disease or wheat allergy. Severe renal impairment. Pregnancy and lactation. Concomitant use with yellow fever vaccine or other live vaccines in immunosuppressed patients.
Special Precautions
Patient with baseline <70% of carbon monoxide diffusing capacity or predicted forced vital capacity (FVC). Renal and hepatic impairment. Monitoring Parameters Monitor CBC with differential and platelet count every week for at least 6 weeks after a dose; liver, renal, and pulmonary function tests at baseline and periodically thereafter. Assess for signs and symptoms of abnormal bleeding and infection.
Adverse Reactions
Significant: Gastrointestinal toxicity (e.g. moderate emesis, stomatitis), hepatotoxicity (e.g. increased transaminases, alkaline phosphatase, and bilirubin), pulmonary toxicity (e.g. infiltrates, fibrosis), nephrotoxicity (e.g. progressive renal failure with decreased kidney size); secondary malignancies, including leukaemia and myelodysplasia (prolonged use). Blood and lymphatic system disorders: Anaemia. Eye disorders: Blindness, optic atrophy, visual disturbances. Gastrointestinal disorders: Nausea, diarrhoea. General disorders and administration site conditions: Ataxia, lethargy. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Abnormal coordination. Psychiatric disorders: Disorientation, dysarthria, confusion. Renal and urinary disorders: Azotaemia. Skin and subcutaneous tissue disorders: Alopecia.
Potentially Fatal: Delayed bone marrow suppression.
Drug Interactions
May potentiate bone marrow toxicity with theophylline and cimetidine. May reduce the anti-tumour effects with phenobarbital.
CIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AD02 - lomustine ; Belongs to the class of alkylating agents, nitrosoureas. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on lomustine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in